{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:23:20Z","timestamp":1764905000119,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"French Ministry of Health","award":["Programme Hospitalier de Recherche Clinique - PHRC 2016 (AOR16028)"],"award-info":[{"award-number":["Programme Hospitalier de Recherche Clinique - PHRC 2016 (AOR16028)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00134-023-07178-6","type":"journal-article","created":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T23:03:02Z","timestamp":1698015782000},"page":"1293-1304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Magnesium sulphate in patients with thrombotic thrombocytopenic purpura (MAGMAT): a randomised, double-blind, superiority trial"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7805-3116","authenticated-orcid":false,"given":"Lara","family":"Zafrani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Canet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Walter-Petrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9rang\u00e8re","family":"Joly-Laffargue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na\u00efke","family":"Big\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mayaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Grang\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Rafat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kada","family":"Klouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"P\u00e8ne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Pichereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baptiste","family":"Duceau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mariotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"7178_CR1","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836\u20132846. https:\/\/doi.org\/10.1182\/blood-2016-10-709857","journal-title":"Blood"},{"key":"7178_CR2","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/jth.12681","volume":"12","author":"A Widemann","year":"2014","unstructured":"Widemann A, Pasero C, Arnaud L et al (2014) Circulating endothelial cells and progenitors as prognostic factors during autoimmune thrombotic thrombocytopenic purpura: results of a prospective multicenter French study. J Thromb Haemost 12:1601\u20131609. https:\/\/doi.org\/10.1111\/jth.12681","journal-title":"J Thromb Haemost"},{"key":"7178_CR3","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","volume":"3","author":"E Mariotte","year":"2016","unstructured":"Mariotte E, Azoulay E, Galicier L et al (2016) Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e237-245. https:\/\/doi.org\/10.1016\/S2352-3026(16)30018-7","journal-title":"Lancet Haematol"},{"key":"7178_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260196","volume":"16","author":"A Renaud","year":"2021","unstructured":"Renaud A, Caristan A, Seguin A et al (2021) Deleterious neurological impact of diagnostic delay in immune-mediated thrombotic thrombocytopenic purpura. PLoS ONE 16:e0260196. https:\/\/doi.org\/10.1371\/journal.pone.0260196","journal-title":"PLoS ONE"},{"key":"7178_CR5","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2019-123720","volume":"134","author":"P Coppo","year":"2019","unstructured":"Coppo P, Cataland S, Peyvandi F et al (2019) Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. Blood 134:2366\u20132366. https:\/\/doi.org\/10.1182\/blood-2019-123720","journal-title":"Blood"},{"key":"7178_CR6","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1007\/s00134-019-05736-5","volume":"45","author":"E Azoulay","year":"2019","unstructured":"Azoulay E, Bauer PR, Mariotte E et al (2019) Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med 45:1518\u20131539. https:\/\/doi.org\/10.1007\/s00134-019-05736-5","journal-title":"Intensive Care Med"},{"key":"7178_CR7","doi-asserted-by":"publisher","first-page":"100945","DOI":"10.1016\/j.blre.2022.100945","volume":"55","author":"M Subhan","year":"2022","unstructured":"Subhan M, Scully M (2022) Advances in the management of TTP. Blood Rev 55:100945. https:\/\/doi.org\/10.1016\/j.blre.2022.100945","journal-title":"Blood Rev"},{"key":"7178_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA et al (2016) Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 374:511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1505533","journal-title":"N Engl J Med"},{"key":"7178_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F et al (2019) Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 380:335\u2013346. https:\/\/doi.org\/10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"key":"7178_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0140-6736(66)90055-9","volume":"1","author":"KD Allanby","year":"1966","unstructured":"Allanby KD, Huntsman RG, Sacker LS (1966) Thrombotic microangiopathy. Recovery of a case after heparin and magnesium therapy. Lancet 1:237\u2013239. https:\/\/doi.org\/10.1016\/s0140-6736(66)90055-9","journal-title":"Lancet"},{"key":"7178_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1160\/TH11-08-0593","volume":"107","author":"S Van Laecke","year":"2012","unstructured":"Van Laecke S, Nagler EVT, Vanholder R (2012) Thrombotic microangiopathy: a role for magnesium? Thromb Haemost 107:399\u2013408. https:\/\/doi.org\/10.1160\/TH11-08-0593","journal-title":"Thromb Haemost"},{"key":"7178_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1160\/TH07-11-0694","volume":"99","author":"J Dong","year":"2008","unstructured":"Dong J, Cruz MA, Aboulfatova K et al (2008) Magnesium maintains endothelial integrity, up-regulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions. Thromb Haemost 99:586\u2013593. https:\/\/doi.org\/10.1160\/TH07-11-0694","journal-title":"Thromb Haemost"},{"key":"7178_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbadis.2004.02.004","volume":"1689","author":"JAM Maier","year":"2004","unstructured":"Maier JAM, Bernardini D, Rayssiguier Y, Mazur A (2004) High concentrations of magnesium modulate vascular endothelial cell behaviour in vitro. Biochim Biophys Acta 1689:6\u201312. https:\/\/doi.org\/10.1016\/j.bbadis.2004.02.004","journal-title":"Biochim Biophys Acta"},{"key":"7178_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1055\/s-0038-1650528","volume":"76","author":"HB Ravn","year":"1996","unstructured":"Ravn HB, Vissinger H, Kristensen SD, Husted SE (1996) Magnesium inhibits platelet activity\u2013an in vitro study. Thromb Haemost 76:88\u201393","journal-title":"Thromb Haemost"},{"key":"7178_CR15","first-page":"7","volume":"18","author":"A Corsonello","year":"2005","unstructured":"Corsonello A, Malara A, De Domenico D et al (2005) Effects of magnesium sulphate on leptin-dependent platelet aggregation: an ex vivo study. Magnes Res 18:7\u201311","journal-title":"Magnes Res"},{"key":"7178_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1046\/j.1365-2141.2002.03967.x","volume":"119","author":"J-R Sheu","year":"2002","unstructured":"Sheu J-R, Hsiao G, Shen M-Y et al (2002) Mechanisms involved in the antiplatelet activity of magnesium in human platelets. Br J Haematol 119:1033\u20131041. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03967.x","journal-title":"Br J Haematol"},{"key":"7178_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/00004872-200018070-00014","volume":"18","author":"R Kh","year":"2000","unstructured":"Kh R, Khullar M, Kashyap M et al (2000) Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens 18:919\u2013926. https:\/\/doi.org\/10.1097\/00004872-200018070-00014","journal-title":"J Hypertens"},{"key":"7178_CR18","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/s0140-6736(02)08778-0","volume":"359","author":"D Altman","year":"2002","unstructured":"Altman D, Carroli G, Duley L et al (2002) Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359:1877\u20131890. https:\/\/doi.org\/10.1016\/s0140-6736(02)08778-0","journal-title":"Lancet"},{"key":"7178_CR19","first-page":"395","volume":"96","author":"D Charoenvidhya","year":"2013","unstructured":"Charoenvidhya D, Manotaya S (2013) Magnesium sulfate maintenance infusion in women with preeclampsia: a randomized comparison between 2 gram per hour and 1 gram per hour. J Med Assoc Thai 96:395\u2013398","journal-title":"J Med Assoc Thai"},{"key":"7178_CR20","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group  (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1\u2013150"},{"key":"7178_CR21","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin Pract 120:c179\u2013c184. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract"},{"key":"7178_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1161\/HYPERTENSIONAHA.108.124651","volume":"53","author":"TM Paravicini","year":"2009","unstructured":"Paravicini TM, Yogi A, Mazur A, Touyz RM (2009) Dysregulation of vascular TRPM7 and annexin-1 is associated with endothelial dysfunction in inherited hypomagnesemia. Hypertension 53:423\u2013429. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.124651","journal-title":"Hypertension"},{"key":"7178_CR23","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1111\/jth.13439","volume":"14","author":"M Le Besnerais","year":"2016","unstructured":"Le Besnerais M, Favre J, Denis CV et al (2016) Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura. J Thromb Haemost 14:1917\u20131930. https:\/\/doi.org\/10.1111\/jth.13439","journal-title":"J Thromb Haemost"},{"key":"7178_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1684\/mrh.2009.0154","volume":"22","author":"AC Ariza","year":"2009","unstructured":"Ariza AC, Bobadilla N, D\u00edaz L et al (2009) Placental gene expression of calcitonin gene-related peptide and nitric oxide synthases in preeclampsia: effects of magnesium sulfate. Magnes Res 22:44\u201349","journal-title":"Magnes Res"},{"key":"7178_CR25","first-page":"1029","volume":"88","author":"A Lattuada","year":"2003","unstructured":"Lattuada A, Rossi E, Calzarossa C et al (2003) Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 88:1029\u20131034","journal-title":"Haematologica"},{"key":"7178_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1179\/1607845412Y.0000000070","volume":"18","author":"S Aref","year":"2013","unstructured":"Aref S, Goda H (2013) Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia. Hematology 18:237\u2013241. https:\/\/doi.org\/10.1179\/1607845412Y.0000000070","journal-title":"Hematology"},{"key":"7178_CR27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10534-021-00328-7","volume":"34","author":"AA Mathew","year":"2021","unstructured":"Mathew AA, Panonnummal R (2021) \u2019Magnesium\u2019-the master cation-as a drug-possibilities and evidences. Biometals 34:955\u2013986. https:\/\/doi.org\/10.1007\/s10534-021-00328-7","journal-title":"Biometals"},{"key":"7178_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0002-8703(00)90051-6","volume":"139","author":"G Gyamlani","year":"2000","unstructured":"Gyamlani G, Parikh C, Kulkarni AG (2000) Benefits of magnesium in acute myocardial infarction: timing is crucial. Am Heart J 139:703. https:\/\/doi.org\/10.1016\/S0002-8703(00)90051-6","journal-title":"Am Heart J"},{"key":"7178_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/nu10020168","volume":"10","author":"N Rosique-Esteban","year":"2018","unstructured":"Rosique-Esteban N, Guasch-Ferr\u00e9 M, Hern\u00e1ndez-Alonso P, Salas-Salvad\u00f3 J (2018) Dietary magnesium and cardiovascular disease: a review with emphasis in epidemiological studies. Nutrients 10:168. https:\/\/doi.org\/10.3390\/nu10020168","journal-title":"Nutrients"},{"key":"7178_CR30","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","volume":"5","author":"F Peyvandi","year":"2021","unstructured":"Peyvandi F, Cataland S, Scully M et al (2021) Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv 5:2137\u20132141. https:\/\/doi.org\/10.1182\/bloodadvances.2020001834","journal-title":"Blood Adv"},{"key":"7178_CR31","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s00134-013-2873-4","volume":"39","author":"E Mariotte","year":"2013","unstructured":"Mariotte E, Blet A, Galicier L et al (2013) Unresponsive thrombotic thrombocytopenic purpura in critically ill adults. Intensive Care Med 39:1272\u20131281. https:\/\/doi.org\/10.1007\/s00134-013-2873-4","journal-title":"Intensive Care Med"},{"key":"7178_CR32","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jth.12826","volume":"13","author":"L Zafrani","year":"2015","unstructured":"Zafrani L, Mariotte E, Darmon M et al (2015) Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost 13:380\u2013389. https:\/\/doi.org\/10.1111\/jth.12826","journal-title":"J Thromb Haemost"},{"key":"7178_CR33","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1182\/blood.2019000748","volume":"134","author":"R Prevel","year":"2019","unstructured":"Prevel R, Roubaud-Baudron C, Gourlain S et al (2019) Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. Blood 134:2209\u20132217. https:\/\/doi.org\/10.1182\/blood.2019000748","journal-title":"Blood"},{"key":"7178_CR34","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","volume":"115","author":"JAK Hovinga","year":"2010","unstructured":"Hovinga JAK, Vesely SK, Terrell DR et al (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115:1500\u20131511. https:\/\/doi.org\/10.1182\/blood-2009-09-243790","journal-title":"Blood"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-023-07178-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-023-07178-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-023-07178-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T08:02:20Z","timestamp":1698912140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-023-07178-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["7178"],"URL":"https:\/\/doi.org\/10.1007\/s00134-023-07178-6","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"type":"print","value":"0342-4642"},{"type":"electronic","value":"1432-1238"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LZ reports receiving fees for lectures for MSD and Sanofi and her institution received a research grant from Jazz Pharmaceuticals. EC received fees for lectures and conference talks and had travel and accommodation expenses related to attending scientific meetings covered by Gilead, Shionogi\u00a0B.V.\u00a0and Sanofi-Genzyme. EA reports receiving fees for lectures from Gilead, Pfizer, Baxter, and Alexion. His research group has been supported by Ablynx, Fisher & Payckle, Jazz Pharma, and MSD, outside the submitted work. NB reports fees and reimbursements for national congresses from Sanofi. AV is a member of the French advisory boards for Sanofi and Takeda. BJL received speaker fees from Sanofi and Takeda. SF reports receiving fees for consulting from Abionyx Pharma and Novartis SA (outside the submitted work), for Scientific Advisory Boards from CSL-Vifor, Sanofi-Genzyme, and Alexion, and for lectures from CSL Vifor and Baxter. SG reports fees for lectures from Alexion. CR reports receiving fees for lectures from Sanofi, Qualworld and M3 global research and has a research contract with Hansa medical. FP report receiving fees for lecture and consulting from Gilead and an institutional grant from ALEXION Pharma. EM reports consulting fees from SANOFI and Takeda. JM, CP, PP, SC, KK,BD and AWP report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The protocol, statistical analysis plan, definition of outcomes, regulatory documents, and other relevant trial materials are available in the supplementary material. According to the sponsor rules, the Assistance Publique\u2013H\u00f4pitaux de Paris is the owner of the data and no use or transmission to a third party can be made without its prior agreement. The trial steering committee will facilitate the use of the trial data and approval will not be unreasonably withheld. Deidentified participant data will be made available to bona fide researchers registered with an appropriate institution. However, the steering committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the trial participants in the consent documentation and ethics approvals, and is compliant with relevant legal and regulatory requirements (eg, relating to data protection and privacy). The steering committee will have the right to review and comment on any draft manuscripts before publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability and sharing"}}]}}